<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006226</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01852</org_study_id>
    <secondary_id>NCI-2012-01852</secondary_id>
    <secondary_id>NCCTG-N9986</secondary_id>
    <secondary_id>CDR0000068148</secondary_id>
    <secondary_id>N9986</secondary_id>
    <secondary_id>N9986</secondary_id>
    <secondary_id>U10CA025224</secondary_id>
    <nct_id>NCT00006226</nct_id>
  </id_info>
  <brief_title>Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia</brief_title>
  <official_title>A Phase II Trial of Thalidomide in Patients With Relapsed Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of thalidomide in treating patients who have&#xD;
      relapsed chronic lymphocytic leukemia. Thalidomide may stop the growth of chronic lymphocytic&#xD;
      leukemia by stopping blood flow to the tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine whether thalidomide can induce objective responses in relapsed B-CLL&#xD;
      patients.&#xD;
&#xD;
      II. To determine the toxicity of thalidomide in this patient population. III. To document if&#xD;
      alterations in vascular growth factors and/or bone marrow angiogenesis patterns correlate&#xD;
      with thalidomide related clinical responses.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive oral thalidomide daily for 4 weeks. Courses repeat every 4 weeks for up to 1&#xD;
      year in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2000</start_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed response, noted as the objective status of CR, nPR, or PR on 2 consecutive evaluations at least 4 weeks apart</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Ninety percent confidence intervals for the true success proportion will be calculated according to the approach of Duffy and Santner.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The Kaplan-Meier method will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The Kaplan-Meier method will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The Kaplan-Meier method will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum grade of each type of toxicity</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Frequency tables will be reviewed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">41</enrollment>
  <condition>B-cell Chronic Lymphocytic Leukemia</condition>
  <condition>Refractory Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (thalidomide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral thalidomide daily for 4 weeks. Courses repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (thalidomide)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (thalidomide)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of chronic lymphocytic leukemia (CLL) evidenced by monoclonal population of&#xD;
             mature CD5+, CD19+, CD23+, and B cells&#xD;
&#xD;
          -  Relapsed after prior treatment for CLL&#xD;
&#xD;
          -  Active disease with 1 or more of the following characteristics:&#xD;
&#xD;
               -  At least 10% weight loss within the past 6 months&#xD;
&#xD;
               -  Fever greater than 100.5 degrees F for at least 2 weeks without evidence of&#xD;
                  infection&#xD;
&#xD;
               -  Night sweats without evidence of infection&#xD;
&#xD;
               -  Evidence of progressive marrow failure with anemia (hemoglobin less than 11 g/dL)&#xD;
                  and/or thrombocytopenia (platelet count less than 100,000/mm^3) (i.e., any stage&#xD;
                  III or IV disease)&#xD;
&#xD;
               -  Autoimmune anemia and/or thrombocytopenia poorly responsive to corticosteroid&#xD;
                  therapy&#xD;
&#xD;
               -  Massive or progressive splenomegaly (i.e., greater than 6 cm below the left&#xD;
                  costal margin or more than 50% increase over 2 months)&#xD;
&#xD;
               -  Progressive lymphadenopathy (i.e., more than 50% increase over 2 months)&#xD;
&#xD;
               -  Progressive lymphocytosis (not due to corticosteroids) with an increase of more&#xD;
                  than 50% over a 2-month period or an anticipated doubling time of less than 6&#xD;
                  months&#xD;
&#xD;
               -  Marked hypogammaglobulinemia or the development of a monoclonal protein in the&#xD;
                  absence of any of the above criteria for active disease are not considered&#xD;
                  evidence of active disease&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  Absolute lymphocyte count greater than 5,000/mm^3&#xD;
&#xD;
          -  No bulky lymph node disease greater than 10 cm in at least 1 dimension except&#xD;
             splenomegaly&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  Absolute neutrophil count at least 500/mm^3&#xD;
&#xD;
          -  Platelet count at least 20,000/mm^3 (in absence of sargramostim [GM-CSF])&#xD;
&#xD;
          -  Hemoglobin at least 8 g/dL&#xD;
&#xD;
          -  Bilirubin no greater than 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST no greater than 2.5 times ULN&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No other active malignancy&#xD;
&#xD;
          -  No peripheral neuropathy (sensory) grade 2 or greater&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use 1 highly effective method of contraception AND 1 additional&#xD;
             effective method of contraception for at least 4 weeks before, during, and for 4 weeks&#xD;
             after study completion&#xD;
&#xD;
          -  No prior allogeneic bone marrow transplantation&#xD;
&#xD;
          -  At least 10 days since prior filgrastim (G-CSF) or GM-CSF&#xD;
&#xD;
          -  No more than 3 prior chemotherapy regimens&#xD;
&#xD;
          -  At least 30 days since prior chemotherapy&#xD;
&#xD;
          -  No concurrent corticosteroids except for adrenal insufficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Kay</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Central Cancer Treatment Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Central Cancer Treatment Group</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>September 11, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>October 7, 2013</last_update_submitted>
  <last_update_submitted_qc>October 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

